

Contents

Session I

Laboratory Animals and the Concept of Alternatives	1
Chairmen: <i>D. Straughan, K. Cussler</i>	

A Short History of the Use of Animals in Vaccine Development and Quality Control	3
<i>C.F.M. Hendriksen</i>	
The Three Rs of Russel & Burch and the Testing of Biological Products	11
<i>M. Balls, D.W. Straughan</i>	

Session II

Testing, Regulations and Three Rs Policy	19
Chairmen: <i>F. Horaud, R. Dabbah</i>	

Alternatives to Animal Testing: Achievements and Recent Developments in the European Pharmacopoeia	21
<i>P. Castle</i>	
WHO Activities Towards the Three Rs in the Development and Control of Biological Products	31
<i>J. Miltien, V. Grachev, A. Padilla, E. Griffiths</i>	
USDA: Progress Toward in Vitro Tests and Other Trends	41
<i>S.A. Goodman</i>	
Alternatives to the Use of Animals in R & D and Quality Control of Veterinary Vaccines: An Industry View	49
<i>C. Verschueren, S. Zänker</i>	
The Views and Policy of the Japanese Control Authorities on the three Rs	53
<i>F. Chino</i>	

Session III

General Aspects	63
Chairmen: <i>R. Winsnes, C. Folkers</i>	

Results and Recommendations of an ECVAM Workshop on «Alternatives to Animal Testing in the Quality Control of Immunobiologicals», Utrecht 16-17.4.1994	65
<i>D.W. Straughan</i>	
The Five Rs: Refinement, Reduction, Replacement. A Regulatory Revolution	67
<i>R.N. Lucken</i>	
Replacement, Reduction or Refinement of Animal Use in the Quality Control of Veterinary Vaccines: Development, Validation and Implementation	73
<i>M.D.O. van der Kamp</i>	

Session IV

Specific Toxicity, Neurovirulence and Other Safety Tests	77
Chairmen: <i>E. Fitzgerald, M. Moos</i>	

Evaluation of New Approaches to Poliovirus Vaccine Neurovirulence Tests	79
<i>D.J. Wood</i>	

Testing of Immunomodulatory Properties in Vitro	85
<i>T. Hartung, A. Sauer, A. Wendel</i>	
Reducing the Use of the Target Animal Batch Safety Test for Veterinary Vaccines	97
<i>B. Roberts, R.N. Lucken</i>	
The Reduction of the Use of Challenge Testing to Provide Evidence of Efficacy in Tests of Immunological Veterinary Medical Products (IVMPs)	103
<i>C.J. Webster</i>	
<i>Session V</i>	
Viral Vaccines	111
Chairmen: <i>A. Osterhaus, L. Bruckner</i>	
Use of Animals in the Development and Control of Viral Vaccines	113
<i>P.D. Minor</i>	
Rat Immunogenicity Assay of Inactivated Poliovirus	121
<i>J.M. Bevilacqua, L. Young, S.W. Chiu, J.D. Sparkes, J.G. Kreeftenberg</i>	
Hepatitis A-Vaccines: a Comparison Between Three Methods of Antigen Determination ...	129
<i>F. Burkhardt, R. Glück, B. Finkel-Jimenez, S. Brantschen</i>	
Development and Evaluation of Alternative Testing Methods for the in vivo NIH Potency Test Used for the Quality Control of Inactivated Rabies Vaccines	137
<i>E. Rooijackers, J. Groen, J. Uittenbogaard, J. van Herwijnen, A. Osterhaus</i>	
Serological Responses in Calves to Vaccines against Bovine Respiratory Syncytial, Infectious Bovine Rhinotracheitis, Bovine Viral Diarrhoea and Parainfluenza -3 Viruses	147
<i>M. Tollis, L. Di Trani, P. Cordioli, E. Vignolo, I. Di Pasquale</i>	
Replacement of Challenge Procedures in the Evaluation of Poultry Vaccines	157
<i>C. Jungbäck, H. Finkler</i>	
<i>Session VI</i>	
New Developments in Vaccine Production and Quality Control	165
Chairmen: <i>F. Brown, C. Hendriksen</i>	
An in Vitro Assay for Acute Pathogenicity of Immunodeficiency Viruses	167
<i>M.T. Dittmar, S. Wagener, P. Fultz, R. Kurth, K. Cichutek</i>	
Detection of Extraneous Agents in Vaccines Using the Polymerase Chain Reaction for Newcastle Disease Virus in Poultry Biologicals	175
<i>L. Bruckner, N. Stäuber, K. Brechtbühl, M.A. Hofmann</i>	
<i>Session VII</i>	
Toxoids Vaccines	183
Chairmen: <i>J. Milstien, P. Castle</i>	
Opportunities to Reduce the Use of Animals in the Potency and Toxicity Testing of Toxoid Vaccines	185
<i>P.A. Knight</i>	
Validation of the Toxin-Binding Inhibition (ToBI) Test for the Estimation of the Potency of the Tetanus Toxoid Component in Vaccines	199
<i>J. van der Gun, A. Akkermans, C. Hendriksen, H. van de Donk</i>	
Use of in Vitro Vero Cell Assay and ELISA in the United States Potency Test of Vaccines Containing Adsorbed Diphtheria and Tetanus Toxoids	207
<i>R.K. Gupta, G.R. Siber</i>	
Vero Cell Assay Validation of an Alternative to the Ph. Eur. Diphtheria Potency Tests	217
<i>A.M. Gommer</i>	

Passive Haemagglutination Tests Using Purified Antigens Covalently Coupled to Turkey Erythrocytes	225
<i>E.H. Relyveld, M. Huet, L. Lery</i>	
<i>Workshop</i>	
Serological Methods and Cell Cultures	243
Chairmen: <i>P. Vannier, R. Gupta</i>	
Comparison of in Vivo and in Vitro Methods for Determining Unitage of Diphtheria Antitoxin in Adsorbed Diphtheria-Tetanus (DT) and Diphtheria-Tetanus-Pertussis (DTP) Vaccines	245
<i>Y.P. Shinde, S.S. Jadhav</i>	
<i>Session VIII</i>	
Bacterial Vaccines	261
Chairmen: <i>S. Houghton, E. Relyveld</i>	
Developments in Pertussis Vaccines Leading to Reduction and Replacement of in Vivo Testing	263
<i>K. Redhead</i>	
Pertussis Serological Potency Test as an Alternative to the Intracerebral Mouse Protection Test	271
<i>A. van der Ark, I. van Straaten-van de Kappelle, C. Hendriksen, H. van de Donk</i>	
Development of a Guinea-Pig Model for Potency/Immunogenicity Evaluation of Diphtheria, Tetanus Acellular Pertussis (DTaP) and <i>Haemophilus influenzae</i> Type b Polysaccharide Conjugate Vaccines	283
<i>R.K. Gupta, R. Anderson, D. Cecchini, B. Rost, P. Griffin Jr., K. Benscoter, J. Xu, L. Montanez-Ortiz, G.R. Siber</i>	
Potency Tests of Diphtheria, Tetanus and Combined Vaccines Suggestion for a Simplified Potency Assay	297
<i>H. Aggerbeck, I. Heron</i>	
Potency Testing of Diphtheria and Tetanus Toxoids. A Reliable, Pragmatic and Economic Approach	303
<i>D.W. Stainer</i>	
<i>Session IX</i>	
Therapeutic Toxins and Monoclonal Antibodies	309
Chairmen: <i>R. Dabbah, H. van de Donk</i>	
Requirements for Valid Alternative Assays for Testing of Biological Therapeutic Agents	311
<i>D. Sesardic</i>	
Investigation of the Product Equivalence of Monoclonal Antibodies for Therapeutic and in Vivo Diagnostic Human Use in Case of Change from Ascitic to in Vitro Production	319
<i>G. Schäffner, M. Haase, S. Giess</i>	
Poster Session	321
Summary and Recommendations	351
Summary and Recommendations	353
<i>H.J.M. van de Donk</i>	